AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06744686
Drug: HT-102
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, 150mg, 300mg, 600mg
Trial: NCT06744686
Drug: HT-102
RxNorm normalized name: 5-HT
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, 150mg, 300mg
Trial: NCT06744816
Drug: Qutenza Patch
RxNorm normalized name: capsaicin Medicated Patch [Qutenza]
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topical
Trial: NCT06745882
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given on day 1 of every 21-day cycle.
Trial: NCT06745882
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given on day 1 of every 21-day cycle.
Trial: NCT06745882
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given on day 1 of every 21-day cycle.
Trial: NCT06745882
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.
Trial: NCT06745882
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given on days 1, 8, and 15 of each 21-day cycle.
Trial: NCT06745882
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given on day 1 of every 21-day cycle.
Trial: NCT06738992
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.
Trial: NCT06738992
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.
Trial: NCT06736704
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is administered via an intramuscular injection. It will be given at a dose of 500 mg (2-250 mg/5 mL injections)
Trial: NCT06738550
Drug: Lactulose oral solution
RxNorm normalized name: lactulose Oral Solution
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours
Trial: NCT06735326
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluzoparib capsule (50mg per capsule) 150mg po BID
Trial: NCT06735326
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab injection (100mg per vial) 7.5mg/kg ivdrip Q3W
Trial: NCT06735326
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel injection 135-175mg/㎡ ivdrip Q3W
Trial: NCT06735326
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin injection AUC=4-5 ivdrip Q3W
Trial: NCT06736080
Drug: MUNC-CD34
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Dosage: ≥ 2 x10e6 CD34/kg after thawing, dose limit: 20x10e6 CD34+ cells/kg~* Route of administration: intravenous, on D0
Trial: NCT06736080
Drug: MUNC-T3
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Dosage: \[1.10e4; 5.10e6\] T-CD3+/kg after thawing,~* Route of administration: intravenous, on D14 post-GT +/- D28 In case of persistent circulating T-cell after the HLH remission at inclusion, the MUNC-CD34 will be completed by MUNC-T3 infusion
Trial: NCT04185441
Drug: Omnic Ocas
RxNorm normalized name: Omni Gel
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0,4 mg
Trial: NCT06581562
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Trial: NCT06581562
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Trial: NCT06743438
Drug: Tenofovir Amibufenamide（TMF）
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Once-daily oral dose of 25 mg TMF were maintained in all participants
Trial: NCT06742138
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intervention Description：Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle
Trial: NCT06742138
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
Trial: NCT06353334
Drug: Butylphthalide and Sodium Chloride Injection
RxNorm normalized name: Butylphthalide
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the experimental group will receive intravenous infusion of 100ml NBP twice daily. Each patient will receive continuous medication for 14 days.
Trial: NCT06353334
Drug: Saline Solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled patients will undergo standard treatment as per international guidelines, concurrently receiving either NBP or placebo therapy. Patients in the control group will receive intravenous infusion of 100ml saline solution twice daily. Each patient will receive continuous medication for 14 days.
Trial: NCT06159166
Drug: Mirdametinib
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is designed to assess Mirdametinib safety and efficacy in two phases: phase 1 tests the safety of up to four dose regimens of Mirdametinib, administered continuously or intermittently (3 weeks on/1 week off) to identify up to two recommended phase 2 doses. Phase 2a of the study will test the safety and efficacy of the recommended phase 2 dose(s) in adults with NF1 and cNF. The following dosing strategy will be assessed in participants ≥ 18 years old with NF1 and a minimum of 12 measurable cNF who desire systemic treatment of their cNF due to disfigurement, pain or itching. Each treatment cycle in this study is 28 days.treatment cycle in this study is 28 days.
Trial: NCT06516289
Drug: HRS-1167
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a highly selective PARP1 inhibitor
Trial: NCT06516289
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a tyrosine kinase inhibitor targeting VEGFR2, PDGFR, and c-kit
Trial: NCT06516289
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a humanised anti-programmed death-1 (anti PD-1) antibody
Trial: NCT05239039
Drug: spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spesolimab
Trial: NCT06067503
Drug: 18F-fluorofuranylnorprogesterone
RxNorm normalized name: 18F-fluorofuranylnorprogesterone
DrugBank: Fluorofuranylnorprogesterone F-18 (DB15282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.
Trial: NCT00000691
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04712942
Drug: Pevonedistat
RxNorm normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive pevonedistat at 20 mg/m2 i.v. (d1,3,5, q4w) up to 12 cycles
Trial: NCT04712942
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: azacitidine is given at a standard dose of 75 mg/m² (d1-7 or 1-5,8,9, q4w) up to 12 cycles
Trial: NCT06551337
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The non-CF bronchiectasis subjects with Vitamin D deficiency would be given 1000 IU and 2000 IU.
Trial: NCT00215423
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02193217
Drug: MT-1303-Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02193217
Drug: MT-1303-High
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193217
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05795647
Drug: Pentoxifylline+Tocopherol
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
Trial: NCT06737458
Drug: Bupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
Trial: NCT06737458
Drug: Bupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
Trial: NCT05697016
Drug: Sivelestat Sodium for Injection
RxNorm normalized name: sodium bicarbonate Powder for Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]
Trial: NCT05160740
Drug: Indocyanine green for injection
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ICG will be injected to participants preoperatively for molecular fluorescence image
Trial: NCT00000812
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04589663
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single inhaled dose of 100 µg mometasone furoate (MF) administered via Twisthaler® on Day 1
Trial: NCT05970666
Drug: TACE with adebrelimab and bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TACE treatment once; Adebrelimab: 20mg/kg, every 3 weeks (21 days); Bevacizumab; 15mg/kg, every 3 weeks (21 days);
Trial: NCT06739317
Drug: First line therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
Trial: NCT06538077
Drug: Oral Branched chain Amino acid
RxNorm normalized name: silk amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active drug BCAA supplement will be dispensed in a dose of 15 gm once daily x 12 weeks
Trial: NCT06538077
Drug: Rifaximin 550 MG
RxNorm normalized name: rifAXIMin 550 MG
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug rifaximin will be dispensed in a dose of 550mg twice daily x 12 weeks
Trial: NCT06538077
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both groups will be treated with will be treated with 30-60 ml lactulose three times a day to ensure passage of 2-3 semisoft stools per day
Trial: NCT06538077
Drug: Placebo for Rifaximin 550mg
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Identical placebo sugar pills will be used as a placebo.
Trial: NCT06719141
Drug: LP352
RxNorm normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
Trial: NCT00005884
Drug: eflornithine
RxNorm normalized name: Eflornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06450314
Drug: Discontinuation of the anti-HER2 maintenance therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heroes is a de-escalation study. Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line setting for their HER2-positive metastatic breast cancer with complete response or partial response at last radiological assessment. Patients with ctDNA negative test at baseline will stop their anti-HER2 targeted therapy during the study
Trial: NCT05289869
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 2 mU/min and increased by 2 mU/min every 30 minutes until adequate contractions achieved, at the discretion of the obstetric providers.
Trial: NCT05858918
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with clopidogrel 75 mg PO daily
Trial: NCT05858918
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with dual antiplatelet drug,aspirin 80 mg PO daily with ticagrelor 90 mg PO twice daily
Trial: NCT06743646
Drug: ZVS101e
RxNorm normalized name: ZVS101e
DrugBank: ZVS101e (DB18424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subretinal injection of ZVS101e
Trial: NCT04971187
Drug: Bintrafusp Alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04971187
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04971187
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04971187
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05736861
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Trial: NCT00002376
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002376
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002376
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002376
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002376
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06740812
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosaprepitant 150mg IV administered over 15 minutes
Trial: NCT06740812
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10mg IV administered over 15 minutes
Trial: NCT05767047
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablets or liquid suspension
Trial: NCT06042153
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.
Trial: NCT05166616
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05166616
Drug: Triptolide Analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
DrugBank: Triptolide (DB12025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03756311
Drug: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
RxNorm normalized name: Nanoparticulate paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06741657
Drug: Litifilimab
RxNorm normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06742866
Drug: Amiodarone Injection
RxNorm normalized name: amiodarone Injection
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer 300 mg of intravenous amiodarone as a loading dose once daily (QD) and 200 mg of oral amiodarone twice daily (BID) within 24 hours postoperatively, and continue for 3 consecutive days.
Trial: NCT06742866
Drug: Sodium Chloride Injection 0.9%
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride injection as a placebo in an amount equivalent to amiodarone injection.
Trial: NCT06741917
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of oral Levofloxacin (500mg/tab) before retrograde intrarenal surgery
Trial: NCT06741917
Drug: Cefmetazole (drug)
RxNorm normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose of intravenous Cefmetazole (1000 mg)before retrograde intrarenal surgery
Trial: NCT06741566
Drug: intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 IU of regular insulin on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Trial: NCT06741566
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5 mic/kg on 3 ml saline 0.9% twice daily for 2 days preoperative via mucosal atomization device at fixed times ( 9 am, 6 pm)
Trial: NCT06742515
Drug: Blinatumomab plus Reduced-dose Chemotherapy
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.